Filgrastim (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Filgrastim" in English language version.

Last modified: 04:28:41, 26 July 2026 (UTC)

Ref.Un. Ref.Website

Global rank English rank

6627web.archive.org

1^st place

3413nih.gov

5^th place

2311europa.eu

62^nd place

100^th place

122drugs.com

529^th place

550^th place

66doi.org

2^nd place

65fda.gov

470^th place

329^th place

42hres.ca

low place

33medicines.org.uk

4,892^nd place

3,451^st place

22hdl.handle.net

66^th place

34^th place

21nytimes.com

7^th place

11hpfb-dgpsa.ca

low place

11canada.ca

1,114^th place

605^th place

11gazetevatan.com

6,696^th place

low place

11arvenilac.com.tr

low place

arvenilac.com.tr (Global: low place; English: low place)

"Products". Arven İlaç. Retrieved 30 August 2024.

canada.ca (Global: 1,114^th place; English: 605^th place)

"Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Archived from the original on 25 March 2024. Retrieved 25 March 2024.

doi.org (Global: 2^nd place; English: 2^nd place)

Moore DC, Pellegrino AE (September 2017). "Pegfilgrastim-Induced Bone Pain: A Review on Incidence, Risk Factors, and Evidence-Based Management". The Annals of Pharmacotherapy. 51 (9): 797–803. doi:10.1177/1060028017706373. PMID 28423916.
Scott WR, Silberstein L, Flatley R, Ardeshna KM, Korostoff N, Dawe S (September 2009). "Cutaneous reaction to pegfilgrastim presenting as severe generalized skin eruption". The British Journal of Dermatology. 161 (3): 717–719. doi:10.1111/j.1365-2133.2009.09371.x. PMID 19614649.
Zimmer BM, Berdel WE, Ludwig WD, Notter M, Reufi B, Thiel E (March 1993). "Fatal spleen rupture during induction chemotherapy with rh GM-CSF priming for acute monocytic leukemia. Clinical case report and in vitro studies". Leukemia Research. 17 (3): 277–283. doi:10.1016/0145-2126(93)90012-a. PMID 8450676.
Rogers KM (June 1992). "Topics in Clinical Pharmacology: Filgrastim, A Myeloid Colony Stimulating Factor". The American Journal of the Medical Sciences. 303 (6): 429–431. doi:10.1097/00000441-199206000-00015. PMID 1376551.
Neymark N (1998). "Assessing the Economic Value of Anticancer Therapies". Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres dans les Recherches Sur le Cancer. Recent Results in Cancer Research. Vol. 148. pp. 1–285. doi:10.1007/978-3-642-72123-6. ISBN 978-3-642-72125-0. PMID 9670279.
Ellery T, Hansen N (2012). Pharmaceutical Lifecycle Management. p. 214. doi:10.1002/9781118266755. ISBN 978-0-470-48753-2.

drugs.com (Global: 529^th place; English: 550^th place)

"Filgrastim Use During Pregnancy". Drugs.com. 13 September 2018. Archived from the original on 18 December 2019. Retrieved 17 December 2019.
"Filgrastim". The American Society of Health-System Pharmacists. Archived from the original on 10 May 2017. Retrieved 8 December 2016.

europa.eu (Global: 62^nd place; English: 100^th place)

ema.europa.eu

"Accofil EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 23 March 2020. Retrieved 2 April 2020.
"Biograstim EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 22 October 2020. Retrieved 2 April 2020.
"Grastofil EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 12 November 2020. Retrieved 2 April 2020.
"Nivestim EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 20 December 2019. Retrieved 20 December 2019.
"Ratiograstim EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 14 August 2020. Retrieved 2 April 2020.
"Zarzio EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 15 October 2019. Retrieved 20 December 2019.
"Zefylti EPAR". European Medicines Agency (EMA). 12 December 2024. Archived from the original on 2 June 2025. Retrieved 16 December 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Tevagrastim EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 16 October 2019. Retrieved 2 April 2020.
"Filgrastim ratiopharm EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 21 January 2021. Retrieved 2 April 2020.
"Filgrastim Hexal EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 30 December 2019. Retrieved 2 April 2020.

ec.europa.eu

"Zefylti PI". Union Register of medicinal products. 14 February 2025. Retrieved 16 February 2025.

fda.gov (Global: 470^th place; English: 329^th place)

accessdata.fda.gov

"Zarxio (filgrastim-sndz)". U.S. Food and Drug Administration (FDA). 20 April 2015. Archived from the original on 20 December 2019. Retrieved 20 December 2019.
"Drug Approval Package: Nivestym (filgrastim-aafi)". U.S. Food and Drug Administration (FDA). 21 February 2019. Archived from the original on 20 December 2019. Retrieved 20 December 2019.
"Drug Approval Package: Releuko". U.S. Food and Drug Administration (FDA). 11 April 2022. Archived from the original on 27 May 2022. Retrieved 2 July 2024.

fda.gov

"FDA Approves Radiation Medical Countermeasure". U.S. Food and Drug Administration (FDA). 30 March 2015. Archived from the original on 30 September 2019. Retrieved 8 September 2023.
"FDA approves first biosimilar product Zarxio". U.S. Food and Drug Administration (FDA) (Press release). 6 March 2015. Archived from the original on 11 December 2015. Retrieved 23 November 2015.

gazetevatan.com (Global: 6,696^th place; English: low place)

finans.gazetevatan.com

"Arven ilaç, Türkiyenin ilk biyobenzer ürününü üretti" [Arven Pharmaceuticals produced Turkey's first biosimilar product]. Vatan Finans (in Turkish). Archived from the original on 11 February 2023.

hdl.handle.net (Global: 66^th place; English: 34^th place)

World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

hpfb-dgpsa.ca (Global: low place; English: low place)

dhpp.hpfb-dgpsa.ca

"Summary Basis of Decision for Filra". Drug and Health Products Portal. 3 June 2025. Retrieved 22 June 2025.

hres.ca (Global: low place; English: low place)

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Nivestym". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
"Summary Basis of Decision (SBD) for Nypozi". Health Canada. 23 October 2014. Archived from the original on 25 September 2022. Retrieved 29 May 2022.

medicines.org.uk (Global: 4,892^nd place; English: 3,451^st place)

"Neupogen 30 MU (0.3 mg/ml) solution for injection - Summary of Product Characteristics (SmPC)". (emc). 7 May 2021. Archived from the original on 1 March 2022. Retrieved 1 March 2022.
"Zarzio 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 4 July 2019. Archived from the original on 20 December 2019. Retrieved 20 December 2019.
"Nivestim 12 MU/ 0.2 ml solution for injection/infusion - Summary of Product Characteristics (SmPC)". (emc). 18 December 2019. Archived from the original on 20 December 2019. Retrieved 20 December 2019.

nih.gov (Global: 5^th place; English: 5^th place)

dailymed.nlm.nih.gov

"Nivestym- filgrastim-aafi injection, solution". DailyMed. 12 August 2025. Retrieved 26 July 2026.
"Releuko- filgrastim injection, solution". DailyMed. 11 March 2022. Archived from the original on 17 March 2022. Retrieved 16 March 2022.
"Filkri- filgrastim-laha injection, solution". DailyMed. 10 July 2026. Retrieved 26 July 2026.
"Nypozi- filgrastim-txid injection". DailyMed. 1 May 2025. Retrieved 26 July 2026.
"Zarxio- filgrastim-sndz injection, solution". DailyMed. 29 August 2025. Retrieved 26 July 2026.
"Nypozi txid- filgrastim-txid injection". DailyMed. 15 January 2026. Retrieved 26 July 2026.
"Neupogen- filgrastim injection, solution". DailyMed. 15 November 2019. Archived from the original on 25 November 2020. Retrieved 20 December 2019.
"Granix- tbo-filgrastim injection, solution". DailyMed. 30 November 2019. Retrieved 8 September 2023.

pubmed.ncbi.nlm.nih.gov

Moore DC, Pellegrino AE (September 2017). "Pegfilgrastim-Induced Bone Pain: A Review on Incidence, Risk Factors, and Evidence-Based Management". The Annals of Pharmacotherapy. 51 (9): 797–803. doi:10.1177/1060028017706373. PMID 28423916.
Scott WR, Silberstein L, Flatley R, Ardeshna KM, Korostoff N, Dawe S (September 2009). "Cutaneous reaction to pegfilgrastim presenting as severe generalized skin eruption". The British Journal of Dermatology. 161 (3): 717–719. doi:10.1111/j.1365-2133.2009.09371.x. PMID 19614649.
Zimmer BM, Berdel WE, Ludwig WD, Notter M, Reufi B, Thiel E (March 1993). "Fatal spleen rupture during induction chemotherapy with rh GM-CSF priming for acute monocytic leukemia. Clinical case report and in vitro studies". Leukemia Research. 17 (3): 277–283. doi:10.1016/0145-2126(93)90012-a. PMID 8450676.
Rogers KM (June 1992). "Topics in Clinical Pharmacology: Filgrastim, A Myeloid Colony Stimulating Factor". The American Journal of the Medical Sciences. 303 (6): 429–431. doi:10.1097/00000441-199206000-00015. PMID 1376551.
Neymark N (1998). "Assessing the Economic Value of Anticancer Therapies". Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres dans les Recherches Sur le Cancer. Recent Results in Cancer Research. Vol. 148. pp. 1–285. doi:10.1007/978-3-642-72123-6. ISBN 978-3-642-72125-0. PMID 9670279.

nytimes.com (Global: 7^th place; English: 7^th place)

Tavernise S, Pollack A (6 March 2015). "F.D.A. Approves Zarxio, Its First Biosimilar Drug". The New York Times. Archived from the original on 23 October 2015. Retrieved 23 November 2015.

web.archive.org (Global: 1^st place; English: 1^st place)

"Releuko- filgrastim injection, solution". DailyMed. 11 March 2022. Archived from the original on 17 March 2022. Retrieved 16 March 2022.
"Accofil EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 23 March 2020. Retrieved 2 April 2020.
"Biograstim EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 22 October 2020. Retrieved 2 April 2020.
"Grastofil EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 12 November 2020. Retrieved 2 April 2020.
"Nivestim EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 20 December 2019. Retrieved 20 December 2019.
"Summary Basis of Decision (SBD) for Nivestym". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
"Summary Basis of Decision (SBD) for Nypozi". Health Canada. 23 October 2014. Archived from the original on 25 September 2022. Retrieved 29 May 2022.
"Ratiograstim EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 14 August 2020. Retrieved 2 April 2020.
"Zarzio EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 15 October 2019. Retrieved 20 December 2019.
"Zefylti EPAR". European Medicines Agency (EMA). 12 December 2024. Archived from the original on 2 June 2025. Retrieved 16 December 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Filgrastim Use During Pregnancy". Drugs.com. 13 September 2018. Archived from the original on 18 December 2019. Retrieved 17 December 2019.
"Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Archived from the original on 25 March 2024. Retrieved 25 March 2024.
"Neupogen 30 MU (0.3 mg/ml) solution for injection - Summary of Product Characteristics (SmPC)". (emc). 7 May 2021. Archived from the original on 1 March 2022. Retrieved 1 March 2022.
"Zarzio 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 4 July 2019. Archived from the original on 20 December 2019. Retrieved 20 December 2019.
"Nivestim 12 MU/ 0.2 ml solution for injection/infusion - Summary of Product Characteristics (SmPC)". (emc). 18 December 2019. Archived from the original on 20 December 2019. Retrieved 20 December 2019.
"Neupogen- filgrastim injection, solution". DailyMed. 15 November 2019. Archived from the original on 25 November 2020. Retrieved 20 December 2019.
"Filgrastim". The American Society of Health-System Pharmacists. Archived from the original on 10 May 2017. Retrieved 8 December 2016.
"FDA Approves Radiation Medical Countermeasure". U.S. Food and Drug Administration (FDA). 30 March 2015. Archived from the original on 30 September 2019. Retrieved 8 September 2023.
"FDA approves first biosimilar product Zarxio". U.S. Food and Drug Administration (FDA) (Press release). 6 March 2015. Archived from the original on 11 December 2015. Retrieved 23 November 2015.
"Zarxio (filgrastim-sndz)". U.S. Food and Drug Administration (FDA). 20 April 2015. Archived from the original on 20 December 2019. Retrieved 20 December 2019.
Tavernise S, Pollack A (6 March 2015). "F.D.A. Approves Zarxio, Its First Biosimilar Drug". The New York Times. Archived from the original on 23 October 2015. Retrieved 23 November 2015.
"Drug Approval Package: Nivestym (filgrastim-aafi)". U.S. Food and Drug Administration (FDA). 21 February 2019. Archived from the original on 20 December 2019. Retrieved 20 December 2019.
"Tevagrastim EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 16 October 2019. Retrieved 2 April 2020.
"Filgrastim ratiopharm EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 21 January 2021. Retrieved 2 April 2020.
"Filgrastim Hexal EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 30 December 2019. Retrieved 2 April 2020.
"Arven ilaç, Türkiyenin ilk biyobenzer ürününü üretti" [Arven Pharmaceuticals produced Turkey's first biosimilar product]. Vatan Finans (in Turkish). Archived from the original on 11 February 2023.
"Drug Approval Package: Releuko". U.S. Food and Drug Administration (FDA). 11 April 2022. Archived from the original on 27 May 2022. Retrieved 2 July 2024.

Filgrastim (English Wikipedia)

arvenilac.com.tr (Global: low place; English: low place)

canada.ca (Global: 1,114th place; English: 605th place)

doi.org (Global: 2nd place; English: 2nd place)

drugs.com (Global: 529th place; English: 550th place)

europa.eu (Global: 62nd place; English: 100th place)

ema.europa.eu

ec.europa.eu

fda.gov (Global: 470th place; English: 329th place)

accessdata.fda.gov

fda.gov

gazetevatan.com (Global: 6,696th place; English: low place)

finans.gazetevatan.com

hdl.handle.net (Global: 66th place; English: 34th place)

hpfb-dgpsa.ca (Global: low place; English: low place)

dhpp.hpfb-dgpsa.ca

hres.ca (Global: low place; English: low place)

hpr-rps.hres.ca

medicines.org.uk (Global: 4,892nd place; English: 3,451st place)

nih.gov (Global: 5th place; English: 5th place)

dailymed.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov

nytimes.com (Global: 7th place; English: 7th place)

web.archive.org (Global: 1st place; English: 1st place)

canada.ca (Global: 1,114^th place; English: 605^th place)

doi.org (Global: 2^nd place; English: 2^nd place)

drugs.com (Global: 529^th place; English: 550^th place)

europa.eu (Global: 62^nd place; English: 100^th place)

fda.gov (Global: 470^th place; English: 329^th place)

gazetevatan.com (Global: 6,696^th place; English: low place)

hdl.handle.net (Global: 66^th place; English: 34^th place)

medicines.org.uk (Global: 4,892^nd place; English: 3,451^st place)

nih.gov (Global: 5^th place; English: 5^th place)

nytimes.com (Global: 7^th place; English: 7^th place)

web.archive.org (Global: 1^st place; English: 1^st place)